1	Enhanced Peer-Group strategies to support prevention of Mother-to-Child HIV
2	transmission leads to increased retention in care in Uganda: A Randomized controlled
3	trial
4	[§] Alexander Amone ¹ , [§] Grace Gabagaya ¹ , Priscilla Wavamunno ¹ , Gordon Rukundo ¹ , Joyce
5	Namale-Matovu ¹ , Samuel S. Malamba ² , Irene Lubega ¹ , Jaco Homsy ³ , Rachel King ³ ,
6	Clemensia Nakabiito ¹ , Zikulah Namukwaya ¹ , Mary Glenn Fowler ^{1,4} and Philippa Musoke ^{1,5}
7	
8	¹ Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda
9	² Uganda Virus Research Institute, Entebbe, Uganda
10	³ Institute for Global Health Sciences, University of California, San Francisco, CA, USA
11	⁴ Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD,
12	USA
13	⁵ Department of Pediatrics and Child Health, Makerere University College of Health Sciences,
14	Kampala, Uganda
15	[§] Corresponding author: Alexander Amone, Makerere University - Johns Hopkins University
16	Research Collaboration, P.O. Box 23491, Kampala, Uganda; Tel/Fax: +256 200 404100 /
17	+256 414 541044.
18	Email: <u>aamone@mujhu.org</u>
19	
20	[§] These authors have contributed equally to the work.
21	Trial registration: ClinicalTrials.gov
22	Key words: HIV; Adherence; Peer support; Option B+; antiretroviral therapy; Retention in
23	care
24	Word count:

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 25 Abstract: 352
- 26 Main text: 3571/3500

27 Abstract

Introduction: Despite scale up of Option B+, long-term retention of women in HIV care during pregnancy and the postpartum period remains an important challenge. We compared adherence to clinic appointments and antiretroviral therapy (ART) at different follow-up time points between enrolment and 24 months postpartum among pregnant women living with HIV and initiating Option B+ randomized to a peer group support, community-based drug distribution and income-generating intervention called "Friends for Life Circles" (FLCs) versus the standard of care (SOC).

Methods: Between 16 May 2016 and 12 September 2017, 540 ART-naïve pregnant women 35 living with HIV at urban and rural health facilities in Uganda were enrolled in the study. 36 Participants were randomized 1:1 to the FLC intervention or SOC and assessed for adherence 37 38 to prevention of mother to child HIV transmission (PMTCT) clinic appointments at 6 weeks, 12 and 24 months postpartum, self-reported adherence to ART at 6 weeks, 6 and 24 months 39 40 postpartum validated by plasma HIV-1 RNA viral load (VL) measured at the same time points, and HIV status and HIV-free survival of infants at 18 months postpartum. We used Log-rank 41 and Chi-Square p-values to test the equality of Kaplan-Meier survival probabilities and hazard 42 rates (HR) for failure to retain in care for any reason by study arm. 43

Results: There was no significant difference in adherence to PMTCT clinic visits or to ART or in median viral loads between FLC and SOC arms at any follow-up time points. Retention in care through the end of study was high in both arms but significantly higher among participants randomized to FLC (86.7%) compared to SOC (79.3%), p=0.022. The adjusted HR of visit dropout was 2.5 times greater among participants randomized to SOC compared to FLC (aHR=2.498, 95% CI: 1.417 – 4.406, p=0.002). Median VL remained < 400 copies/ml in both arms at 6 weeks, 6 and 24 months postpartum.</p>

- 51 Conclusions: Our findings suggest that programmatic interventions that provide group
- 52 support, community based ART distribution and income-generation activities may contribute
- 53 to retention in PMTCT care, HIV-free survival of children born to women living with HIV,
- 54 and to the elimination of mother to child HIV transmission (MTCT).

55 INTRODUCTION

Prevention of mother-to-child HIV transmission (PMTCT) remains a pillar in the global fight against HIV/AIDS. "Option B+" for PMTCT recommends lifelong triple ART for all pregnant and breastfeeding women living with HIV regardless of immune status. Option B+ also recommends protecting these women's newborns with daily Nevirapine or Zidovudine from birth through 4-6 weeks of age, regardless of the infant feeding method (1).

In April 2012, the World Health Organisation (WHO) recommended Option B+ as the PMTCT treatment option which would provide the highest clinical benefits and programmatic advantages for both the care and treatment of mothers living with HIV and perinatal HIV prevention (1). Compared to previous proven PMTCT regimens, Option B+ was easier to deliver and more effective in reducing mother-to-child HIV transmission (MTCT) (2-4). Based on these recommendations, a number of low-income countries including Uganda adopted Option B+ as standard of care with the aim to eliminate MTCT of HIV.

Despite this progress and the proven efficacy of Option B+(5), poor adherence to lifelong ART 68 and low retention in care of pregnant and postpartum women living with HIV has remained an 69 70 important programmatic challenge to the implementation of Option B+ especially in low resource settings (6-11). A review of studies done between 2000-2020 identified barriers to 71 taking ART among pregnant women that included financial constraints limiting access to food 72 and transport, and side effects of the therapy (12). Additionally, high dropout rates from 73 74 PMTCT care have been documented after delivery and at two years of follow-up among 75 mothers living with HIV (13-15), suggesting that service integration and linking mothers to routine ART services were important determinants of retention in care. These findings 76 highlighted the critical need for innovative interventions to promote retention in HIV care and 77 adherence to ART for the successful implementation of option B⁺. 78

In Uganda, adherence counseling by clinic-based midwives trained in counseling and the use 79 of "buddies" as well as family involvement are recommended by the Ministry of Health (MOH) 80 to support maternal ART adherence and retention in care (16). However, there is limited focus 81 on the use of community-based support interventions. Studies in other resource-limited settings 82 have shown better PMTCT intervention adherence with the use of community-based 83 counseling, support groups and home visits (17-20). Additionally, studies in Kenya have 84 85 demonstrated that peer support from community-based mentor mothers to improve ART adherence and retention in care was well accepted among women living with HIV (21, 22). 86

Given these challenges, we conducted a randomized controlled trial (RCT) to compare adherence to PMTCT clinic appointments and ART at different time points within 24 months of postpartum follow-up among women started on ART while pregnant and randomized to an enhanced peer group support intervention including community-based drug distribution and income-generating activities called "Friends for Life Circles" (FLCs) versus the MOH standard of care (SOC).

93

94 METHODS

We conducted an open-label RCT between 16 May 2016 and May 2020 at Mulago National 95 Referral Hospital and two health centers (HCs III & IV) in Kampala, the capital city of Uganda; 96 and at rural Mityana District Hospital (74 kms northwest of Kampala) as well as five HCs III 97 and IV in Mityana district. Participants were recruited from 16 May 2016 to 12 September 98 2017 and follow up was completed on 26 May 2020. The selected HCs represent different 99 levels of maternal health care offered in Uganda. The study was implemented and coordinated 100 by the Makerere University–Johns Hopkins University (MUJHU) Research Collaboration 101 102 based at Mulago Hospital in Kampala.

103 Enrollment and randomization procedures

We enrolled pregnant women living with HIV initiated on PMTCT Option B+ who were: ≥ 18 years old, confirmed pregnant by urine dipstick, confirmed HIV-positive by rapid HIV testing as per National PMTCT Guidelines, being ART-naïve and beginning Option B+ ART within 30 days of enrolment into the study, residing within 20 km of the study clinic, not planning to move out of the clinic catchment area within 2 years, agreeing to be home visited, and providing written informed consent.

Pregnant women testing HIV-positive through the routine National PMTCT Program and starting Option B+ were referred to study counselors by the clinic PMTCT counselors for prescreening and scheduled to return to the study clinics for consent procedures within one month of starting once daily Option B+ ART. HIV rapid testing followed the national and WHO algorithms (23) using three sequential antibody rapid tests: Abbott Determine Rapid HIV 1 Test, Abbott Laboratories, USA; Stat Pak Rapid HIV-1 Test, Chembio Diagnostic Systems, USA; and Unigold HIV Rapid Test, Trinity Biotech, Ireland.

Eligible and consenting women were then randomized 1:1 irrespective of the study sites to SOC control arm or FLC intervention arm. The randomization list was computer-generated by the data manager based at MUJHU using random-sized block groups that included consecutive intervention numbers with corresponding random intervention assignments. Each pregnant woman was assigned unique participant identification number and authors had no access to information that could identify individual participants during or after data collection

After randomization, participants were assessed for socioeconomic status, ARV drug adherence and stigma. A questionnaire addressing participants' experiences with stigmatization and discrimination at family and community levels was administered at baseline, 126 12 months post-enrolment and at end of study. An additional needs assessment questionnaire was administered to participants enrolled in the FLC arm at enrolment, 1-year post enrolment and every 6 months thereafter until the end of study. This was to assess individuals' achievements and to document challenges related to group activities and participation in income-generating activities (IGAs) and its benefits, skills acquired and training needs.

131 FLC Intervention and SOC controls

The FLC intervention (hereafter 'FLC') included community-based enhanced peer group support, IGAs and community-based drug distribution. Participants in the FLC arm formed dynamic peer support groups based on women's home addresses documented by Geographical Positioning System (GPS). Groups consisted of 8-10 participants who attended monthly meetings in their communities. Sustainable livelihood study assistants and study counselors participated in and documented FLC group activities. Each FLC group was supported by one peer mother who had similar social background and/or life experiences as FLC participants.

During monthly FLC group meetings, study counselors distributed ART and Cotrimoxazole
and offered psychosocial support on follow-up clinic visits and drug adherence through
individual and group counseling while emphasizing peer support among participants.

142 FLC groups also offered skills building in a variety of IGAs such as goat rearing, bakery, crafts making, liquid soap making, book binding and charcoal briquette making. These were chosen 143 by the participants and implemented as a group or as individuals with the guidance of a study 144 IGA Advisor. All FLC groups were linked to local government bodies for sustainability, 145 registration and access to Community Development Driven grants funded by the District Local 146 Government to support the implementation of livelihood projects for community-based groups. 147 SOC arm participants received counseling from clinic PMTCT counselors and collected their 148 drug refills on an individual basis from the PMTCT clinics where they were enrolled as per 149

MOH guidelines (16). SOC arm participants participated voluntarily in family support groupswhenever available at their respective health facility as recommended by the MOH (16).

152 Follow-up procedures

At each study site, all study participants were followed at a dedicated clinic for all scheduled 153 and unscheduled visits and were given transport reimbursement for scheduled study visits. 154 Scheduled visits included a first visit within the initial four weeks post-enrolment, then monthly 155 thereafter until delivery, at delivery, at 6 and 14 weeks postpartum, and quarterly thereafter 156 157 from 6 months through 24 months postpartum (end of follow-up). At each of these visits, FLC participants were counseled by study counselors on drug adherence and family planning while 158 SOC participants were counseled by PMTCT counselors. Study counselors administered 159 160 questionnaires on ART adherence, stigma, and socio-economic status to all participants at each 161 scheduled clinic visit.

Participants were terminated from the study if they missed four or more consecutive scheduledstudy visits, withdrew consent, relocated outside study area, or died.

164

165 Infant procedures

All infants born to study participants were enrolled in the study and received daily Nevirapine syrup from birth up to 6 weeks of age regardless of the infant feeding method. Infants were tested routinely at 6 weeks of age for HIV by DNA PCR and at 18 months of age by rapid HIV antibody test as part of the National Early Infant HIV Diagnosis Program (23).

170 **Outcomes and measures**

The primary outcomes of interest included adherence to PMTCT clinic appointments at 6
weeks, 12 and 24 months postpartum and adherence to Option B+ ART at 6 weeks, and 6 and
24 months postpartum.

174 Complete adherence to visits was defined as having attended the 4 scheduled quarterly visits 175 at the end of each of the first and second years of postpartum follow-up as defined by the MOH 176 (16). Scheduled visits were determined to have been adhered to on the basis of a completed 177 visit within a 3-week window on either side of the scheduled visit date.

Retention in care was defined as the proportion of participants who were not terminated from the study prior to the end of follow-up (24 months postpartum). Causes for termination included participant relocation out of the study area, withdrawal from the study, loss to follow-up, miscarriage, referral outside the study facility, and death. The study defined loss to follow-up as not attending 3 consecutive scheduled study visits. Retention in care was calculated as 1 minus the proportion of women terminated for any such reason before the end of follow-up.

As a second primary outcome, we compared maternal ART adherence using self-report at 6 weeks and 6 and 24 months postpartum among all study participants. We validated selfreports by comparing VL measurements for all participants at 6 weeks, 6 and 24 months postpartum.

All participants were asked to self-assess the number of complete ART doses they missed in the past three days. Self-reported ART adherence was then calculated as 1 minus the proportion of self-reported doses missed in the past 3 days.

Laboratory measures of ARV adherence were used to validate self-reports using viral suppression below 400 copies/mL. At the time of writing the study protocol, this limit was considered as viral suppression by Uganda MOH (16). VL measurements were performed at the Infectious Diseases Institute (IDI) Core Laboratory, Kampala, Uganda, a central laboratory certified by the American College of Pathologists. Nucleic acids were extracted and tested for HIV-1 RNA using the COBAS® AmpliPrep/ COBAS® TaqMan® HIV-1 Test procedure

following the manufacturer's instructions (Roche Molecular Systems, Inc., Branchburg, NJ,
08876 USA) (25).

Virological failure was defined as median viral load persistently above 1000 copies/ml for two consecutive viral load measurements within a three-month interval after at least 6 months of initiating ART. The final drug adherence variable at each time point was dichotomized as 'not adhering' if viral load was \geq 400 copies/ml irrespective of the level of self-reported adherence, or as 'adhering' if self-reported adherence in the last 3 days was \geq 95% and viral load was <400 copies/ml.

Lastly, the HIV status and the HIV-free survival of children born to study participants were assessed at their 6 week and 18-month postpartum visits as per the National PMTCT program recommendation and practice.

209

210 Statistical Analyses

We estimated a target sample size of at least 270 women living with HIV needed to be enrolled in each of the study arms to provide 90% power at 5% significance level to detect a difference of 15% or more in adherence to visits and drugs or in virological suppression between the intervention and control arms. Follow-up time was calculated in person-years, with each participant contributing time in years from enrolment to censoring at the date when a participant was lost to follow-up, died or reached the end of study.

We compared participants' baseline characteristics in the FLC and SOC arms by testing for differences in proportions using Fisher's exact p-values. Maternal adherence to at least 4 scheduled PMTCT clinic appointments at the end of each year of postpartum follow-up, adherence to ART and retention in care, as well as the HIV status of children were also summarized using proportions and chi-square p-values. We used the Wilcoxon–Breslow– Gehan test to assess the difference in HIV-free survival of participants' children between the FLC and SOC arms. Log rank and Chi-Square p-values were used to test the equality of Kaplan-Meier survival probabilities and hazard rates for failure to retain in care for any reason by study arm. Cox Proportional Hazard regression model adjusted for unbalanced baseline variables was used to estimate the hazard rate ratio of failing to retain participants in care with 95% confidence intervals between the FLC and the SOC arms.

228 Ethical and regulatory considerations

The study was approved by Uganda's National Council of Science and Technology (UNCST), the Joint Clinical Research Centre (JCRC) Institutional Review Board (IRB), as well as the IRBs of Johns Hopkins University (JHU) and the University of California San Francisco (UCSF). Written informed consent was obtained from all study participants by study counselors in the presence of an impartial witness before enrolment in the study.

234 **RESULTS**

Between May 2016 and September 2017, a total 1192 HIV-positive pregnant women were
assessed for study eligibility. Of these, 45 % (540/1192) were found eligible and randomized
1:1 to either the intervention or the control arm until each arm accrued 270 participants across
all study sites (Fig 1).

239 Figure 1 – Trial Profile

240

241 Baseline demographic characteristics

Table 1 provides the number of participants, clinic visits made, and person-years of follow-up
by baseline socio-demographic characteristics of the study population stratified by study arm.
These results show that despite randomization, there were significant differences between the

- two study arms in participants' educational level, gravidity, HIV status disclosure to partner
- and monthly income.
- 247 Table 1. Baseline socio-demographic characteristics of study population (N=540)
- 248
- 249 Adherence to PMTCT clinic appointments
- 250 There was no statistically significant difference between the intervention and control arms in
- the number of women who started or completed their postpartum visits at 6 weeks postpartum
- 252 or in the first or second year of follow-up (Table 2).

253 Table 2. Adherence to PMTCT clinic appointments

254

255 Retention in care

Overall, retention in care was high across both study arms with 83.0% of all participants remaining in care at the end of follow-up (Table 3). Significantly, more women were retained in care at the end of follow-up in the FLC arm (86.7%) compared to the SOC arm (79.3%, p= 0.0221). Also, more women were terminated before the end of follow-up due to relocation in the SOC arm (n=27, 10.0%) compared to the FLC arm (n=12, 4.4%).

261 Table 3. Retention in care by study arm at the end of study

262

There was a significant difference between the Kaplan-Meier survival functions for failure to remain in care until the end of study (24 months postpartum visit) between the control and intervention arms (Wilcoxon-Breslow test for equality of survivor functions Chi^2 (1) = 11.94, p-value = 0.0005) (Figure 2). Overall, the estimated proportion of participants retained in care was high, with 87.0% of all participants remaining in care until the end of the study.

Figure 2. Kaplan-Meier survival curves for retention in care up to 24 months

269 postpartum.

270

271 Adherence to ART

- Table 4 shows that participants self-reported optimal adherence to taking >95% of their ART
- 273 medication in the last 3 days at their 6 weeks, 6 and 24 months postpartum visits. There was
- no statistically significant difference in optimal adherence to ART between the arms. The
- 275 median viral loads of participants at each of these time points were <100 copies/ml with no
- statistically significant differences between the two arms.

277 Table 4. Adherence to Option B+ ART by study arm

278

279

280 **Predictors of retention in care**

281 Cox-proportional hazard regression models were used to assess the effect measure of

intervention on being retained in care. All baseline variables with p < 0.1 at the univariate level

were included in the multivariate model and using a backward elimination method, only those

variables with p < 0.05 were kept in the final model.

285

Table 5: Multivariate Cox proportional hazard model for failure to remain in care

287

Table 5 shows that the rate of dropout from care was 2.5 times greater among participants randomized to the SOC arm versus the FLC arm (aHR=2.498, 95% CI: 1.417 - 4.406, p=0.002). Participants enrolled from rural health facilities and those aged 15-24 years were also significantly less likely to be retained in care compared to their urban (p=0.021) or their older counterparts (p=0.035) respectively. Educational level, gravidity, disclosure status and
income were not significant predictors of retention in care and were not included for analysis
in the final model.

295 HIV-free survival of children

Of 492 women with a visit at 18 months postpartum, 8 of their 431 (1.9%) tested infants tested positive for HIV. Most (7/8) of these infants had tested positive to HIV by the 6th week postpartum visit. The proportion of HIV-positive children born to mothers enrolled in the FLC arm (1.4%) was not significantly different from that observed in the SOC arm (2.4%) (p=0.472).

By the 18-month postpartum visit, the HIV-free survival of children born to mothers in the FLC arm was 93.8% [95% CI: 89.9 - 96.2] compared to 83.0% [95% CI: 75.9 - 87.7] among children born to mothers in the SOC arm. The difference between the two arms was significant (p=0.0031).

305

306 Discussion

In this RCT, we found that there was no statistical difference through 24 months of postpartum follow-up in adherence to PMTCT clinic visits or ART among pregnant and postpartum women started on Option B+ ART during pregnancy and randomized to the FLC intervention or the MOH SOC services. We however found that women in the FLC arm were statistically significantly more likely to have remained in PMTCT care through 2 years postpartum compared to the SOC arm.

This is comparable to the study by Masereka et al, which found that 87.9% of women were retained in care after being initiated on Option B+ in Uganda (26). Our data is also consistent with a study from Malawi which found that at 24 months after initiation of Option B+ ART,
retention in the peer group models was 80% and 83% in the facility-based and communitybased arms respectively, compared with 60% in the standard of care arm (17). This may explain
the absence of a statistically significant difference between the intervention and control arm
when it came to adherence to PMTCT clinic appointments.

In both arms of this RCT, 87% or more participants self-reported optimal adherence to taking their ART at 6 weeks, 6- and 24-months postpartum and the median viral load levels of participants were under 100 copies/ml at each of these time points with no significant difference between the FLC and SOC arms. We did not find fluctuations in longitudinal adherence during the postpartum period.

A systematic review by Wubneh et al in Ethiopia found that the pooled estimate of good adherence to Option B+ ART among 1852 pregnant and lactating women was 84% (27), which is comparable to our finding. Our finding is also consistent with a cohort study done in Malawi that found 90%-100% adherence to ART among women on Option B+ observed from 4 to 21 months postpartum (28). That study used pharmacy records to measure adherence as opposed to self-reports and VL validation which may limit comparisons with our study.

Although we found high self-reported adherence to ART that corroborated with low median 331 viral loads, we did not find significant differences in these outcomes between the FLC and 332 333 SOC arms at any follow-up time points. The close correlation between these outcomes echo the findings of a study among 452 women on PMTCT care and treatment in South Africa where 334 it was found that a raised viral load was consistently associated with lower median adherence 335 336 scores (29). However, the lack of a more distinct outcome from the FLC intervention may result from a study effect or still a 'contamination' between the FLC and SOC arms among both study 337 staff and participants in the study facilities (30). 338

Few children were found infected with HIV postnatally and most of them were likely infected 339 in utero or at birth given the timing of their positive test result. However, our finding that HIV-340 free survival of children born to mothers in the FLC arm was significantly higher than those in 341 the SOC arm is noteworthy as it implies that more children died of non-HIV causes in the latter 342 arm. Many factors may have accounted for this outcome but peer support, less variation in drug 343 adherence and increased economic security (through IGAs) and thus the ability of mothers to 344 345 better feed and care for their babies all are plausible explanations supported by an ample literature (31-37). 346

347 Limitations

Our study's main limitation is that our RCT was individually and not cluster randomized, which may have resulted in cross-contamination between the FLC and the SOC arms in the same clinics over the long-term follow-up period. Contamination could have also occurred when study staff attended to both FLC and SOC participants at the same clinic. Additionally, all study participants were given transport reimbursement for their study visits which may have positively influenced adherence to study visits. Lastly, the feasibility of our intervention would depend on its cost and cost-effectiveness, which we did not assess.

355 **Conclusions**

Our study found that the FLC intervention significantly increased retention in care and HIVfree survival of children of pregnant mothers living with HIV through 24 months postpartum. These findings are encouraging and suggest that programmatic interventions such as the FLC may contribute to the goal of eliminating MTCT of HIV in Uganda. We recommend scaling up peer group support, community drug distribution and income-generation intervention strategies in the context of PMTCT.

363

364 **Conflict of Interest Statement**

365 The authors declare that they have no conflict interests.

366 Authors' contributions

- JNM, IL, RK, JH, CN, ZN, MN, MGF and PM contributed to the conception and design of the
- 368 study. AA and GG wrote the original draft. GR contributed to data curation. SM carried out
- 369 statistical analysis. AA, GG, JH, PW, SM, RK, SM, CN and PM reviewed and edited the
- 370 manuscript. All authors approved the final manuscript.

371 Acknowledgements

- We would like to thank the FLC for Option B+ study team who were vital in the collection of
- this data and the study participants without whom this study would not have been possible.

374 Funding:

The Friends for Life Circles for Option B+ study which was funded by NIH/Eunice Kennedy
Shriver National Institute of Child Health and Human Development (NICHD) grant #
IR01HD080476-01.

378

379 **References**

- 380 1. World Health Organization. (2012). Programmatic update: use of antiretroviral drugs for
- treating pregnant women and preventing HIV infection in infants: Executive Summary.
- 382 World Health Organization. <u>https://apps.who.int/iris/handle/10665/70892</u>
- 383 2. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for
- treating and preventing HIV infection: recommendations for a public health approach.
- World Health Organization; 2016.
- 386 3. DiCarlo, A.L., Gachuhi, A.B., Mthethwa-Hleta, S., Shongwe, S., Hlophe, T., Peters, Z.J.,
- 387 Zerbe, A., Myer, L., Langwenya, N., Okello, V. and Sahabo, R., 2019. Healthcare
- 388 worker experiences with Option B+ for prevention of mother-to-child HIV transmission
- in eSwatini: findings from a two-year follow-up study. BMC health services

390 research, 19(1), pp.1-12 PMID: 30940149 PMCID: PMC6444445

- 4. Muyunda, B., Musonda, P., Mee, P., Todd, J. and Michelo, C., 2020. Effectiveness of
- lifelong ART (Option B+) in the prevention of mother-to-child transmission of HIV
- 393 programme in Zambia: observations based on routinely collected health data. Frontiers in

394 Public Health, p.401. PMID: 32010656 PMCID: PMC6978742

- 5. Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, et al. Benefits and
- risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med. 2016
- **397** Nov;375(18):1726–37. PMID: 27806243 PMCID: PMC5214343
- 398 6. Haas AD, Tenthani L, Msukwa MT, Tal K, Jahn A, Gadabu OJ, Spoerri A,
- 399 Chimbwandira F, van Oosterhout JJ, Keiser O. Retention in care during the first 3 years
- 400 of antiretroviral therapy for women in Malawi's option B+ programme: an observational
- 401 cohort study. The Lancet HIV. 2016 Apr 1;3(4):e175-82.

402	7.	Atanga PN, Ndetan HT, Fon PN, Meriki HD, Muffih TP, Achidi EA, Hoelscher M,
403		Kroidl A. Using a composite adherence tool to assess ART response and risk factors of
404		poor adherence in pregnant and breastfeeding HIV-positive Cameroonian women at 6
405		and 12 months after initiating option B+. BMC pregnancy and childbirth. 2018
406		Dec;18(1):1-0.
407	8.	Gamell A, Luwanda LB, Kalinjuma AV, Samson L, Ntamatungiro AJ, Weisser M, et al.
408		Prevention of mother-to-child transmission of HIV Option B+ cascade in rural Tanzania:
409		The One Stop Clinic model. Charpentier C, editor. PLoS One. 2017 Jul;12(7):e0181096.
410		PMID: 28704472 PMCID: PMC5507522
411	9.	Ritchie LM, van Lettow M, Pham B, Straus SE, Hosseinipour MC, Rosenberg NE, Phiri
412		S, Landes M, Cataldo F. What interventions are effective in improving uptake and
413		retention of HIV-positive pregnant and breastfeeding women and their infants in
414		prevention of mother to child transmission care programmes in low-income and middle-
415		income countries? A systematic review and meta-analysis. BMJ open. 2019 Jul
416		1;9(7):e024907.
417	10.	Mukosha M, Chiyesu G, Vwalika B. Adherence to antiretroviral therapy among HIV
418		infected pregnant women in public health sectors: a pilot of Chilenje level one Hospital
419		Lusaka, Zambia. The Pan African Medical journal. 2020;35.
420	11.	Mukose AD, Bastiaens H, Makumbi F, Buregyeya E, Naigino R, Musinguzi J, Van Geertruyden
421		JP, Wanyenze RK. What influences uptake and early adherence to Option B+ (lifelong
422		antiretroviral therapy among HIV positive pregnant and breastfeeding women) in Central
423		Uganda? A mixed methods study. PloS one. 2021 May 5;16(5):e0251181.
424	12.	Mwamba Kalungwe, Scovia Nalugo Mbalinda, Thamary Karonga, Niza Rean Simwanza,
425		Catherine M. Mumba Mtambo, Mathew Nyashanu. Exploring barriers to antiretroviral

426		therapy adherence among pregnant women: A scoping literature review. Gyn &
427		Obstetrics 2022, 159(2):343-350. https://doi.org/10.1002/ijgo.14130
428	13.	Knettel BA, Cichowitz C, Ngocho JS, Knippler ET, Chumba LN, Mmbaga BT, et al.
429		Retention in HIV Care during Pregnancy and the Postpartum Period in the Option B+
430		Era: Systematic Review and Meta-Analysis of Studies in Africa. Vol. 77, Journal of
431		Acquired Immune Deficiency Syndromes. Lippincott Williams and Wilkins; 2018. p.
432		427–38. PMID: 29287029 PMCID: PMC5844830
433	14.	Kiragu K, Collins L, Von Zinkernagel D, Mushavi A. Integrating PMTCT into maternal,
434		newborn, and child health and related services: Experiences from the global plan priority
435		countries. J Acquir Immune Defic Syndr. 2017;75:S36-42. PMID: 28398995
436	15.	Mushamiri I, Belai W, Sacks E, Genberg B, Gupta S, Perry HB. Evidence on the
437		effectiveness of community-based primary health care in improving HIV/AIDS
438		outcomes for mothers and children in low- and middle-income countries: Findings from
439		a systematic review. J Glob Health. 2021 Jul 10;11:11001. doi: 10.7189/jogh.11.11001.
440		PMID: 34327001; PMCID: PMC8284540
441	16.	Ministry of Health- Uganda. Consolidated Guidelines on the prevention and treatment of
442		HIV and AIDS in Uganda. 2018;(September):327
443	17.	Rosenberg NE, van Lettow M, Tweya H, Kapito-Tembo A, Bourdon CM, Cataldo F,
444		Chiwaula L, Sampathkumar V, Trapence C, Kayoyo V, Kasende F. Improving PMTCT
445		uptake and retention services through novel approaches in peer-based family-supported
446		care in the clinic and community: a three-arm cluster randomized trial (PURE Malawi).
447		Journal of acquired immune deficiency syndromes. 2014 Nov 1;67(0 2):S114.
448	18.	Phiri S, Tweya H, Van Lettow M, Rosenberg NE, Trapence C, Kapito-Tembo A, et al.
449		Impact of facility- and community-based peer support models on maternal uptake and

450		: N/-1:?-	D I	THY/		£ 41 4	-1.114	
450	and retention	in Malawi s	s option B+	- HIV p	brevention o	of mother-to)-child ti	ransmission

- 451 program: A 3-arm cluster randomized controlled trial (PURE Malawi). J Acquir Immune
- 452 Defic Syndr. 2017;75:S140–8. PMID: 28498183
- 453 19. Lyatuu GW, Naburi H, Mwashemele S, Lyaruu P, Urrio R, Simba B, Philipo E, Kibao A,
- 454 Kajoka D, Sando D, Orsini N. Effect of peer-mother interactive programme on
- 455 prevention of mother-to-child HIV transmission outcomes among pregnant women on
- 456 anti-retroviral treatment in routine healthcare in Dar es Salaam, Tanzania. PLOS Global
- 457 Public Health. 2022 Mar 9;2(3):e0000256.
- 458 20. Pugh LE, Roberts JS, Viswasam N, Hahn E, Ryan S, Turpin G, Lyons CE, Baral S,
- 459 Hansoti B. SYSTEMATIC REVIEW OF INTERVENTIONS AIMED AT IMPROVING
- 460 HIV ADHERENCE TO CARE IN LOW-AND MIDDLE-INCOME COUNTRIES.
- 461 Journal of Infection and Public Health. 2022 Aug 28.
- 462 21. Helova A, Onono M, Abuogi LL, Hampanda K, Owuor K, Odwar T, Krishna S,
- 463 Odhiambo G, Odeny T, Turan JM. Experiences, perceptions and potential impact of
- 464 community-based mentor mothers supporting pregnant and postpartum women with HIV
- in Kenya: a mixed-methods study. Journal of the International AIDS Society. 2021
- 466 Nov;24(11):e25843.
- 467 22. Wanga I, Helova A, Abuogi LL, Bukusi EA, Nalwa W, Akama E, Odeny TA, Turan JM,

468 Onono M. Acceptability of community-based mentor mothers to support HIV-positive

- 469 pregnant women on antiretroviral treatment in western Kenya: a qualitative study. BMC
- 470 pregnancy and childbirth. 2019 Dec;19(1):1-2.

471

472 23. Ministry of Health- Uganda. National HIV Testing Services Policy and Implementation473 Guidelines

474	24.	Omonaiye C	, Nicholson P	, Kusljic S	, Manias E. A	meta-analy	sis of effectiveness	s of
-----	-----	------------	---------------	-------------	---------------	------------	----------------------	------

- interventions to improve adherence in pregnant women receiving antiretroviral therapy in
- 476 sub-Saharan Africa. International Journal of Infectious Diseases. 2018 Sep 1;74:71-82.

477 26. .

- 478 25. Roche Diagnostics. COBAS ® AmpliPrep/COBAS ® TaqMan ® HIV-1 Test package
 479 insert. :1–36.
- 480 26. Masereka EM, Ngabirano TD, Osingada CP, Wiltshire CS, Castelnuovo B, Kiragga AN.

481 Increasing retention of HIV positive pregnant and breastfeeding mothers on option-b

482 plus by upgrading and providing full time HIV services at a lower health facility in rural

483 Uganda. BMC public health. 2019 Dec; 19(1):1-6.

- Wubneh CA, Mekonnen BD, Delelegn MW, Atalell KA. Adherence to option B+ and its
 association with disclosure status and counseling among HIV-positive pregnant and
 lactating women in Ethiopia: systematic review and meta-analysis. Public Health. 2022
 Oct 1;211:105-13.
- 488 28. Haas AD, Msukwa MT, Egger M, Tenthani L, Tweya H, Jahn A, Gadabu OJ, Tal K,

489 Salazar-Vizcaya L, Estill J, Spoerri A. Adherence to antiretroviral therapy during and

490 after pregnancy: cohort study on women receiving care in Malawi's option B+ program.

```
491 Clinical infectious diseases. 2016 Nov 1;63(9):1227-35.
```

492 29. Phillips T, Brittain K, Mellins CA, Zerbe A, Remien RH, Abrams EJ, Myer L, Wilson

- 493 IB. A Self-Reported Adherence Measure to Screen for Elevated HIV Viral Load in
- 494 Pregnant and Postpartum Women on Antiretroviral Therapy. AIDS Behav. 2017
- 495 Feb;21(2):450-461. PMID: 27278548; PMCID: PMC5145763

496 30.	Magill N.	Knight R,	McCrone P.	, Ismail K.	Landau S. A	scoping	review	of the	problems
---------	-----------	-----------	------------	-------------	-------------	---------	--------	--------	----------

and solutions associated with contamination in trials of complex interventions in mental

health. BMC medical research methodology. 2019 Dec;19(1):1-3.

- 499 31. Berg RC, Page S, Øgård-Repål A. The effectiveness of peer-support for people living
- 500 with HIV: A systematic review and meta-analysis. PLoS One. 2021 Jun

501 17;16(6):e0252623.

- 502 32. Yotebieng M, Thirumurthy H, Moracco KE, Edmonds A, Tabala M, Kawende B, Wenzi
- 503 LK, Okitolonda EW, Behets F. Conditional cash transfers to increase retention in
- 504 PMTCT care, antiretroviral adherence, and postpartum virological suppression: a
- randomized controlled trial. Journal of acquired immune deficiency syndromes (1999).

506 2016 Aug 1;72(Suppl 2):S124.

507 33. Liu JX, Shen J, Wilson N, Janumpalli S, Stadler P, Padian N. Conditional cash transfers
508 to prevent mother-to-child transmission in low facility-delivery settings: evidence from a
509 randomised controlled trial in Nigeria. BMC pregnancy and childbirth. 2019
510 Dec;19(1):1-2.

511 34. Camlin CS, Marson K, Ndyabakira A, Getahun M, Emperador D, Byamukama A,

512 Kwarisiima D, Thirumurthy H, Chamie G. Understanding the role of incentives for

achieving and sustaining viral suppression: A qualitative sub-study of a financial

incentives trial in Uganda. Plos one. 2022 Jun 24;17(6):e0270180.

515 35. Imbaya CL, Odhiambo-Otieno GW, Okello-Agina BM. Adherence levels to antenatal

- regimens of NVP and AZT among HIV+ women receiving PMTCT treatment at
- 517 Pumwani Maternity Hospital in Nairobi, Kenya. AIDS 2008 XVII International AIDS
- 518 Conference: Abstract no MOPE05192008

519	36. Chime OH, Arinze	-Onyia SU, Obionu	CN. Do peer support	groups have an effect on
-----	----------------------	-------------------	---------------------	--------------------------

- 520 medication adherence? A study among people living with HIV/AIDS in Enugu State,
- 521 Nigeria. Proc Singapore Health Conference. 2018;27(4):256–64.
- 522 37. Fahey CA, Njau PF, Katabaro E, Mfaume RS, Ulenga N, Mwenda N, Bradshaw PT,
- 523 Dow WH, Padian NS, Jewell NP, McCoy SI. Financial incentives to promote retention in
- 524 care and viral suppression in adults with HIV initiating antiretroviral therapy in
- 525 Tanzania: a three-arm randomised controlled trial. The Lancet HIV. 2020 Nov
- 526 1;7(11):e762-71.

527





Table 2. Adherence to PMTCT clinic appointments

	Adherence to PMTCT clinic appointments Primary outcomes measure (A)	At 6 Weel Postpartur	cs n visit	Number attended at least 4 quarterly visits in the 1 st year postpartum measured at the 12 Months Postpartum visit		Number attended at least 4 quarterly visits in the 2 nd year postpartum measured at the 24 Months Postpartum visit	
		FLC ARM	ARM	FLC ARM	ARM	FLC ARM	SOC ARM
medRxiv preprint	doi: 1///ac.//doi.ac./40.1404/2028.04.15.22020485: this version	posted April 17, 202	2. The convright hal	for for this proprint			
(which was no	t certified by one review) is the author/funder, who has gran It is made available under a CC-BY 4.0 Ir	ed medfixivaticens ternational ficense . (89.6%)	e tootsqlayzinenrer (85.6%)	rin2i2p3r/2602 (85.1%)	197/247 (79.8%)	187/245 (76.3%)	168/224 (75.0%)
	Includes all women who started						
	the time window of interest (6						
	the second year of postpartum						
	follow-up)						
	Fisher's Exact p-values	P=0	.192	P=0	.129	P=0	.748
	As treated analysis:	242/262	231/247	223/245	197/224	187/229	168/207
	In the data all succession with a	(92.4%)	(93.5%)	(91.0%)	(87.9%)	(81.7%)	(81.2%)
	completed the time window of						
	interest (6 weeks postpartum, the						
	first or the second year of						
	postpartum follow-up)						
	Fisher's Exact p-values	P=0	.730	P=0	.294	P=0.903	

$\mathbf{PP} = \mathbf{postpartum}$

- ^a Women who attended \geq 4 quarterly visits in the 1st year PP
- ^b Women who attended > 4 quarterly visits in the 2nd year PP

Table 3. Retention in care by study arm at the end of study

			Study Arm, n (%)
Follo	ow-up status at end of study	FLC=270 n (column %)	SOC=270 n (column %)	Total=540 n (column %)
Tern	ninated before end of follow-up	36 (13.3%)	56 (20.7%)	92 (17.0%)
T	erminated due to relocation	12 (4.4%)	27 (10.0%)	39 (7.2%)
L	ost to follow-up	3 (1.1%)	3 (1.1%)	6 (1.1%)
W	ithdrawn from study	15 (5.5%)	17 (6.3%)	32 (5.9%)
T	ermination due to death	1 (0.4%)	6 (2.2%)	7 (1.3%)
0	ther - Miscarriage/Referred/No time	2 (0.7%)	3 (1.1%)	5 (0.9%)
medRxiv preprint doi: 1 (which was not per	https://doi.org/10.1101/2023.04.15.23288495; this version posted April 17 titied by permission is the author/funder, who has granted medRxiv a It is made available under a CC-BY 4.0 International lice	, 2023. The copyright holder for thi icense to display the preprint in pense .	s preprint petuity. 0 (0.0%)	3 (0.6%)
Miss	ed last 24 months PP visit	0 (0.0%)	6 (2.2%)	6 (1.1%)
Com	pleted follow-up	234 (86.7%)	208 (77.0%)	442 (81.9%)
Rete	ntion in care	1 - (36/270)	1 - (56/270)	1 - (92/540)
		(00.770)	(79.370)	(03.070)
p-val	lue†	0.02	21	

n = Number of individuals; PP = Postpartum

[†]Chi-square (1) = 8.453

	Adherence to Option B+ ART	6 weeks p	ostpartum	6 months postpartum 24 months pos			
	Self-reported	FLC	SOC	FLC	SOC	FLC	SOC
	Proportion of doses	11/242	9/232	29/225	34/216	22/223	20/200
	missed in past 3 days*	(4.6%)	(3.9%)	(12.9%)	(15.7%)	(9.9%)	(10.0%)
	Adherence to taking ARV	1 - 4.6%	1 - 3.9%	1 - 12.9%	1 – 15.7%	1 – 9.9%	1-10.0%
	for option B+ **	(95.4%)	(96.1%)	(87.1%)	(84.3%)	(90.1%)	(90.0%)
med	p-values	p=0.718		p=0.122		p=0.644	
(vi	hich was not certified by peer teview) is the author/full is made available u	nder, who has granted med nder a CC EV 4 0 Internatio	Rxiv a license to display th nal license	e preprint in perpetuity.	SOC	FLC	SOC
	Median log ₁₀ VL (IQR) [†]	1.80	1.86	1.64	1.52	1.30	1.30
		(1.30-2.61)	(1.34-2.78)	(1.30-2.66)	(1.30-3.79)	(1.30-2.77)	(1.30-2.83)
	Median copies/mL (IQR) †	63 cp/ml	72 cp/ml	44 cp/ml	33 cp/ml	20 cp/ml	20 cp/ml
		(20-407)	(22-603)	(20-457)	(20-6,166)	(20-589)	(20-676)

Table 4. Adherence to Option B+ ART by study arm

* No. of women with sub-optimal adherence in the past 3 days prior to clinic visit / Total number of women visiting the clinic and responding to the past 3 days adherence questions at each visit of interest (6 weeks pp, 6 months and 24 months pp). These results have accounted for the validation of self-reported adherence using viral load measures (Self-reported adherence with a viral load <400 copies/ml was classified as Adherent and self-reported adherence with a viral load ≥400 copies/ml was classified as non-adherent)

** 1 minus the proportion of women self-reported as sub-optimally taking their medication in the past 3

days

[†] At 6 weeks postpartum, we used VL test results for samples taken at delivery. Samples taken at 6 weeks

were stored for analysis at a later time

Variables		N=540	Hazard Ratio (HR)	[95% Conf. Interval]	p-value		
Study arm	Study arm FLC		1.000				
	SOC	270	2.498	1.417 - 4.406	0.002		
Urban status	Urban	401	1.000				
	Rural	139	0.412	0.195 - 0.868	0.020		
Age	15-24 years	259	1.000				
	25-34 years	241	0.546	0.311 - 0.959	0.035		
	35+ years	40	0.585	0.179 - 1.906	0.373		
medRxiv preprint doi: https://doi.org/c0.1101/2023.04.1523236499.11hts version posted April 17, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a cense to display the preprint in perpetuity.							
It is made	Ganda	301	0.625	0.374 - 1.044	0.073		

Table 5: Multi-variable Cox Proportional Hazard model for failure to remain in care

Trial Profile





Table 1. Baseline socio-demographic characteristics of study population (N=5	40)
--	------------

	Intervention								
	(FLC Arm)								
Socio-demographic	Person	-years	Total no. of		Person-years		Total no. of		
characteristics at baseline	of follow-up		women in		of follow-up		women in		
	[PYFU] for		FLC Arm		[PYFU] for		SOC Arm		
	ALL visits				ALL visits				
Rxiv preprint doi: https://doi.org/10.1101/2023.04.15.2328849 hich was not certified by peer review) is the author/funder, It is made available under a	Visits this version p who has grante CC-BY 4.0 Int	PYFU osted April 17, 2 od medRxiv a lic ernational licens	N 2023. The cop ense to display e .	col yright holder y the preprin	Visits for this preprint t in perpetuity.	PYF U	N	col %	p-value
Enrolment Sites									
Kampala-Urban	2455	392.9	200	74.1	2271	354.1	201	74.4	
Mityana-Rural	907	144.5	70	25.9	912	142.8	69	25.6	0.922
Marital Status									
Married/Co-habiting	2607	418.2	209	77.4	2565	399.0	217	80.4	0.655
Never Married	502	77.4	40	14.8	389	61.1	33	12.2	
Separated/Divorced/	253	41.8	21	7.8	229	36.8	20	7.4	
Widowed									
Age									
18-24 years	1415	222.9	116	43.0	1659	257.0	143	53.0	0.068
25-34 years	1654	267.7	130	48.2	1318	206.5	111	41.1	
35+ years	293	46.8	24	8.9	286	33.3	16	5.9	
Educational level									
Tertiary	194	30.9	16	5.9	116	17.9	9	3.3	0.021*
Secondary	1429	227.3	113	41.9	1810	282.4	145	53.7	
Primary	1611	260.2	131	48.5	1140	176.8	103	38.2	
No education	128	18.9	10	3.7	117	19.7	13	4.8	
Religion									
Catholic	1185	188.0	93	34.4	1100	169.8	93	34.4	0.615
Protestant	858	139.8	69	25.6	724	115.4	57	21.1	
Moslem	676	106.0	56	20.7	688	110.4	60	22.2	
SDA/Pentecostal/others	643	103.6	52	19.3	671	101.3	60	22.2	
Tribe									
Non-Ganda	1495	240.7	123	45.6	1292	202.0	116	43.0	0.543
Ganda	1867	296.6	147	54.4	1891	294.9	154	57.0	

Gravidity					ĺ				
1	613	96.1	51	18.9	630	96.6	54	20.0	0.016*
2	663	106.2	54	20.0	1011	159.7	84	31.1	
3	943	151.1	75	27.8	684	106.9	60	22.2	
4+	1143	184.0	90	33.3	858	133.7	72	26.7	
Disclosure to partner									
Yes	1270	200.5	100	37.0	1396	214.6	118	43.7	0.040*
No	2036	328.1	165	61.1	1640	259.3	140	51.9	
No partner	56	8.8	5	1.9	147	23.0	12	4.4	
Disclosure to relatives medRxiv preprint doi: https://doi.org/10.1101/2023.04.15.23288495	; this version p	osted April 17, 2	2023. The cop	yright holder	for this preprin	t			
(which was not certified by peer review) is the author/funder, It is made available under a	who has grante CC- <mark>B</mark> 40 nte	d medRxiv a lic ernational licens	ense to displat e . 106	y the preprin 39.3	t in perpetuity. 1179	186.6	97	35.9	0.423
No	2029	324.7	164	60.7	2004	310.3	173	64.1	
Monthly Income (USD)*									
1.35-40.5	591	94.2	46	17.1	772	121.2	65	24.1	0.046*
>40.5-135.1	946	149.5	75	27.8	627	96.5	51	18.9	
>135.1	602	99.0	48	17.8	589	90.4	47	17.4	
Don't know	1223	194.7	101	37.4	1195	188.8	107	39.6	
TOTAL No. of	3362	538.4	270	50.0	3183	497.2	270	50.0	
Participants									
TOTAL No. of All visits			3362	51.4			3183	48.6	
No. of Scheduled PP visits			2017	83.0			1854	76.3	

Legend: PP = postpartum; * significant difference (p<0.05)

† 1 USD =3,650 UG Shillings (UGX) at the time of enrolment

PYFU= Person Years of Follow Up. Follow-up time was calculated in person-years, with each participant contributing time in years from enrolment to censoring at either: the date of death, or the date loss to follow-up was reported, or end of follow-up date (24-month postpartum visit)